ÂÜÀòÂÒÂ×

Jean-Paul Prieels is a member of Icosavax’s scientific advisory board. He started his industrial career at Petrofina in 1983 as biotechnology manager and joined GlaxoSmithKline Biologicals (now GSK Vaccines) in 1987. His responsibilities gradually expanded to lead the vaccine preclinical R&D development activities as Senior Vice President of Research and Development at GlaxoSmithKline Biologicals in Rixensart, Belgium, until 2011. His career spans from basic research to applied research and product development. He was instrumental in the development of several commercially available vaccines, including Rotarix, Cervarix, and Synflorix. Today, he is director at NCardia, Themis, Leukocare, Nouscom, DNAlytics, and PDC*Line Pharma. He is a member of the scientific advisory board of Singapore Bioprocessing Technology Institute, CureVac, Imcyse, and Vaximm, and a member of the European Vaccine Initiative Board of Stakeholders. Dr. Prieels holds a Ph.D. in biochemistry from Université Libre de Bruxelles in Belgium.